philipn authored on Oct. 25, 2020, 9:53 p.m. | | Additions are marked like this |
Bromhexine is a cough medication, available over-the-counter in much of the world, that has been proposed as a COVID-19 therapeutic. Potential mechanism of action
Bromhexine has been speculated to inhibit the TMPRSS2 serine protease used by SARS-CoV-2. In an August 6th, 2020 NIH paper, bromhexine did not directly inhibit TMPRSS2 in vitro. Study author Matt Hall noted: "The fact bromhexine is not inhibiting TMPRSS2 doesn't mean it can't work against COVID, and other recent literature in cell models supports our data." -Matt Hall, NIH researcher COVID-19 clinical trialsAdd here. See also | Bromhexine is a cough suppressant, available over-the-counter in much of the world, that has been proposed as a COVID-19 therapeutic. Potential mechanism of action
Bromhexine has been speculated to inhibit the TMPRSS2 serine protease used by SARS-CoV-2. In an August 6th, 2020 NIH paper, bromhexine did not directly inhibit TMPRSS2 in vitro. Study author Matt Hall noted: "The fact bromhexine is not inhibiting TMPRSS2 doesn't mean it can't work against COVID, and other recent literature in cell models supports our data." -Matt Hall, NIH researcher COVID-19 clinical trialsIn a small (n=78) open-label, randomized clinical trial of bromhexine was conducted in Iran (July 2020): "There was a significant reduction in ICU admissions (2 out of 39 vs. 11 out of 39, P=0.006), intubation (1 out of 39 vs. 9 out of 39, P=0.007) and death (0 vs. 5, P=0.027) in the bromhexine treated group compared to the standard group. No patients were withdrawn from the study because of adverse effects." As of October, 2020, there are two clinical trials of bromhexine registered with clinicaltrials.gov currently recruiting participants:
Bromhexine for COVID-19 research reviewsSee also |
